{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Response rate was measured as complete, partial and hematologic improvement by modified IWG criteria. For complete remission the following must be present for four weeks in a bone marrow aspirate and biopsy: \\<5% myeloblasts, normal maturation of all cell lines, persisted dysplasia. Peripheral blood counts need to be hemoglobin \\>11 g/dL, neutrophils \\>1000/mm3, platelets\\>100000/mm3, blasts 0%. Partial remission requires all criteria for complete remission except blasts decreased by \\>50% over pretreatment. Stable disease is defined as failure to achieve at least partial remission, but no evidence of progression for \\> 8 weeks. Failure is defined as death during tre3atment or disease progression characterized by worsening of cytopenias, increase in percentage of bone marrow blasts, or progression to a more advanced MDS FAB subtype than pretreatment.","groups":[{"description":"All participants enrolled.\n\nClofarabine: Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.","id":"OG000","title":"All Evaluable Patients"}],"paramType":"NUMBER","populationDescription":"Two patients were not eligible for analysis.","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"The Overall Response Rate in Response to Low Dose Daily Oral Clofarabine in Patients With High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (Dysplastic Type).","type":"PRIMARY","unitOfMeasure":"participants who experienced a response"}